Psychedelics, which activate serotonin 5-HT2A receptors, show promise for treating depression and PTSD but also produce effects resembling schizophrenia symptoms such as psychosis and cognitive deficits. The neurobiological overlap between psychedelics and schizophrenia involves shared serotonergic and glutamatergic pathways. Psychedelics may counteract synaptic loss seen in schizophrenia by promoting neuroplasticity, but their psychotic effects complicate dosing. Subpsychedelic or microdosing regimens and non-hallucinogenic analogs are being explored as safer alternatives. Further exploratory, preclinical, and clinical studies are needed to determine tolerability and effective dosing for schizophrenia therapy.
A retrospective analysis of patient-reported outcomes found that psychiatric adverse events emerged during ketamine treatment for major depressive disorder. The text does not specify the frequency, severity, or nature of these events, nor does it provide comparative data or a control group. The analysis suggests that such events can occur, but the magnitude and clinical significance remain unclear based solely on the abstract.
This thematic collection introduces the field of psychedelic medicine, focusing on therapeutic applications and implications for future research. The collection covers various aspects of psychedelic-assisted therapies, including their potential to treat mental health conditions, the mechanisms underlying their effects, and the challenges and opportunities for integrating these treatments into clinical practice. It highlights the need for further investigation into safety, efficacy, and ethical considerations, as well as the importance of understanding the subjective experiences and neurobiological changes associated with psychedelic substances. The collection aims to provide a comprehensive overview of the current state of psychedelic medicine and guide future research directions.